Literature DB >> 22306014

pp-GalNAc-T13 induces high metastatic potential of murine Lewis lung cancer by generating trimeric Tn antigen.

Yasuyuki Matsumoto1, Qing Zhang, Kaoru Akita, Hiroshi Nakada, Kazunori Hamamura, Noriyo Tokuda, Akiko Tsuchida, Takeshi Matsubara, Tomoko Hori, Tetsuya Okajima, Keiko Furukawa, Takeshi Urano, Koichi Furukawa.   

Abstract

In order to analyze the mechanisms for cancer metastasis, high metastatic sublines (H7-A, H7-Lu, H7-O, C4-sc, and C4-ly) were obtained by repeated injection of mouse Lewis lung cancer sublines H7 and C4 into C57BL/6 mice. These sublines exhibited increased proliferation and invasion activity in vitro. Ganglioside profiles exhibited lower expression of GM1 in high metastatic sublines than the parent lines. Then, we established GM1-Si-1 and GM1-Si-2 by stable silencing of GM1 synthase in H7 cells. These GM1-knockdown clones exhibited increased proliferation and invasion. Then, we explored genes that markedly altered in the expression levels by DNA microarray in the combination of C4 vs. C4-ly or H7 vs. H7 (GM1-Si). Consequently, pp-GalNAc-T13 gene was identified as up-regulated genes in the high metastatic sublines. Stable transfection of pp-GalNAc-T13 cDNA into C4 (T13-TF) resulted in increased invasion and motility. Then, immunoblotting and flow cytometry using various antibodies and lectins were performed. Only anti-trimeric Tn antibody (mAb MLS128), showed increased expression levels of trimeric Tn antigen in T13-TF clones. Moreover, immunoprecipitation/immunoblotting was performed by mAb MLS128, leading to the identification of an 80 kDa band carrying trimeric Tn antigen, i.e. Syndecan-1. Stable silencing of endogenous pp-GalNAc-T13 in C4-sc (T13-KD) revealed that primary tumors generated by subcutaneous injection of T13-KD clones showed lower coalescence to fascia and peritoneum, and significantly reduced lung metastasis than control clones. These data suggested that high expression of pp-GalNAc-T13 gene generated trimeric Tn antigen on Syndecan-1, leading to the enhanced metastasis.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22306014     DOI: 10.1016/j.bbrc.2012.01.086

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

1.  De novo expression of human polypeptide N-acetylgalactosaminyltransferase 6 (GalNAc-T6) in colon adenocarcinoma inhibits the differentiation of colonic epithelium.

Authors:  Kirstine Lavrsen; Sally Dabelsteen; Sergey Y Vakhrushev; Asha M R Levann; Amalie Dahl Haue; August Dylander; Ulla Mandel; Lars Hansen; Morten Frödin; Eric P Bennett; Hans H Wandall
Journal:  J Biol Chem       Date:  2017-11-29       Impact factor: 5.157

2.  Revisiting the human polypeptide GalNAc-T1 and T13 paralogs.

Authors:  María Florencia Festari; Felipe Trajtenberg; Nora Berois; Sergio Pantano; Leslie Revoredo; Yun Kong; Patricia Solari-Saquieres; Yoshiki Narimatsu; Teresa Freire; Sylvie Bay; Carlos Robello; Jean Bénard; Thomas A Gerken; Henrik Clausen; Eduardo Osinaga
Journal:  Glycobiology       Date:  2016-11-22       Impact factor: 4.313

3.  A strategy for generating cancer-specific monoclonal antibodies to aberrant O-glycoproteins: identification of a novel dysadherin-Tn antibody.

Authors:  Catharina Steentoft; Max Fuhrmann; Federico Battisti; Julie Van Coillie; Thomas D Madsen; Diana Campos; Adnan Halim; Sergey Y Vakhrushev; Hiren J Joshi; Hans Schreiber; Ulla Mandel; Yoshiki Narimatsu
Journal:  Glycobiology       Date:  2019-04-01       Impact factor: 4.313

4.  A transmembrane C-terminal fragment of syndecan-1 is generated by the metalloproteinase ADAM17 and promotes lung epithelial tumor cell migration and lung metastasis formation.

Authors:  Tobias Pasqualon; Jessica Pruessmeyer; Sarah Weidenfeld; Aaron Babendreyer; Esther Groth; Julian Schumacher; Nicole Schwarz; Bernd Denecke; Holger Jahr; Pascale Zimmermann; Daniela Dreymueller; Andreas Ludwig
Journal:  Cell Mol Life Sci       Date:  2015-04-26       Impact factor: 9.261

5.  Polypeptide N-Acetylgalactosaminyltransferase 13 Contributes to Neurogenesis via Stabilizing the Mucin-type O-Glycoprotein Podoplanin.

Authors:  Yingjiao Xu; Wenjie Pang; Jishun Lu; Aidong Shan; Yan Zhang
Journal:  J Biol Chem       Date:  2016-09-14       Impact factor: 5.157

6.  Trimeric Tn antigen on syndecan 1 produced by ppGalNAc-T13 enhances cancer metastasis via a complex formation with integrin α5β1 and matrix metalloproteinase 9.

Authors:  Yasuyuki Matsumoto; Qing Zhang; Kaoru Akita; Hiroshi Nakada; Kazunori Hamamura; Akiko Tsuchida; Tetsuya Okajima; Keiko Furukawa; Takeshi Urano; Koichi Furukawa
Journal:  J Biol Chem       Date:  2013-06-27       Impact factor: 5.157

7.  Significant Impact of Immunogen Design on the Diversity of Antibodies Generated by Carbohydrate-Based Anticancer Vaccine.

Authors:  Zhaojun Yin; Sudipa Chowdhury; Craig McKay; Claire Baniel; W Shea Wright; Philip Bentley; Katarzyna Kaczanowska; Jeffrey C Gildersleeve; M G Finn; Lbachir BenMohamed; Xuefei Huang
Journal:  ACS Chem Biol       Date:  2015-08-11       Impact factor: 5.100

Review 8.  The Cosmc connection to the Tn antigen in cancer.

Authors:  Tongzhong Ju; Rajindra P Aryal; Matthew R Kudelka; Yingchun Wang; Richard D Cummings
Journal:  Cancer Biomark       Date:  2014-01-01       Impact factor: 4.388

Review 9.  Biosynthetic Machinery Involved in Aberrant Glycosylation: Promising Targets for Developing of Drugs Against Cancer.

Authors:  Andréia Vasconcelos-Dos-Santos; Isadora A Oliveira; Miguel Clodomiro Lucena; Natalia Rodrigues Mantuano; Stephen A Whelan; Wagner Barbosa Dias; Adriane Regina Todeschini
Journal:  Front Oncol       Date:  2015-06-25       Impact factor: 6.244

10.  Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation.

Authors:  Zhi-Qiang Wang; Magdalena Bachvarova; Chantale Morin; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Alexandra Sebastianelli; Dimcho Bachvarov
Journal:  Oncotarget       Date:  2014-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.